Single-Dose Amphotericin B for Cryptococcal Meningitis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
   Trial
2. Use of DOOR and Win-Ratio Analysis in a Secondary Evaluation of a Histoplasmosis Clinical Trial.Open forum infectious diseases · 2026
   Article
3. New 2030 Global Targets for Histoplasmosis from International Society for Human and Animal Mycology (ISHAM) 2025 Histoplasmosis Working Group.Emerging infectious diseases · 2026
   Article
4. Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023
   Review

Corrections and comments

• Commented on by
  Single-Dose Amphotericin B for Cryptococcal Meningitis. Reply.2022
• Comment on
  Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.2022

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as